Context Therapeutics Signs Strategic Research Collaborations for Apristor® with Leading Breast Cancer Investigators

PHILADELPHIA, PA--(BUSINESS WIRE)— Context Therapeutics, a clinical stage biopharmaceutical company dedicated to the treatment of hormone driven cancers, today announces it has signed multiple research collaborations to further understand the role of progesterone receptor (PR) signaling and its blockade to overcome resistance mechanisms underlying metastatic breast cancer (mBCa).

Read More